Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00219102
Status:
COMPLETED
Last Update Posted:
2020-02-11
First Post:
2005-09-12
Brief Title:
A Clinical Study to Evaluate Safety Efficacy of the Combination of Aliskiren Valsartan Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 12-week Randomized Double-blind Placebo Controlled Parallel Group Study Evaluating the Efficacy Safety of Aliskiren in Patients With Diabetes Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg Hydrochlorothiazide 25 mg
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartanhydrochlorothiazide in diabetic patients with essential hypertension not adequately responsive to the combination of valsartan and hydrochlorothiazide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None